RESEARCH



Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: systematic review and network meta-analysis

Jae Joon Park¹⁺, Kwang Taek Kim²⁺, Eun Ji Lee³, Joey Chun^{1,4}, Serin Lee^{1,5}, Sung Ryul Shim^{6,7*} and Jae Heon Kim^{1*}

Abstract

Background Despite the publication of several meta-analyses regarding the efficacy of certain therapies in helping individuals with interstitial cystitis (IC) / bladder pain syndrome (BPS), these have not provided a comprehensive review of therapeutic strategies. The study aimed to determine the efficacy of various therapies for IC/BPS and identify potential moderating factors using randomized controlled trials (RCTs).

Methods We queried the PubMed, Cochrane, and Embase databases to identify prospective RCTs using inclusion criteria: 1) patients diagnosed with IC, 2) interventions included relevant treatments, 3) comparisons were a specified control or placebo, 4) outcomes were mean differences for individual symptoms and structured questionnaires. The pairwise meta-analysis and network meta-analysis (NMA) were performed to compare the treatments used in IC/BPS. Hedges' *g* standardized mean differences (SMDs) were used for improvement in all outcomes using random-effects models. Efficacy outcomes included individual symptoms such as pain, frequency, urgency, and nocturia, as well as structured questionnaires measuring IC/BPS symptoms.

Results A comprehensive literature search was conducted which identified 70 RCTs with 3,651 patients. The analysis revealed that certain treatments, such as instillation and intravesical injection, showed statistically significant improvements in pain and urgency compared to control or placebo groups in traditional pairwise meta-analysis. However, no specific treatment demonstrated significant improvement in all outcomes measured in the NMA. The results of moderator analyses to explore influential variables indicated that increasing age was associated with increased nocturia, while longer follow-up periods were associated with decreased frequency.

Conclusion This systematic review and meta-analysis provide insights into the efficacy of various treatments for IC. Current research suggests that a combination of therapies may have a positive clinical outcome for patients with IC, despite the fact that treatment for this condition is not straightforward.

Trial registration PROSPERO CRD42022384024

[†]Jae Joon Park and Kwang Taek Kim are the co-first authors.

*Correspondence: Sung Ryul Shim sungryul.shim@gmail.com Jae Heon Kim piacekjh@hanmail.net Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

Keywords Cystitis, Interstitial, Pain, Lower Urinary Tract Symptoms, Urinary Bladder, Overactive, Medication Therapy Management, Administration, Intravesical, Physical Therapy Modalities

Background

A constellation of incapacitating systems, which encompass discomfort in the suprapubic region, nocturia and micturition frequency and urgency, are characteristic of interstitial cystitis (IC), a condition also referred to as bladder pain syndrome (BPS). Typically, such symptoms occur when the bladder is full, and dissipate once urine has been passed [1, 2]. In addition to these symptoms, a major complaint of patients suffering from IC is pelvic pain, which originates from the urethra, vagina or rectum, amongst other viscera [3]. There is at present no standard definition for this condition, nor consensus regarding its management, recommended therapy or the treatment period required [4].

A range of drugs directed towards the treatment of IC have been the topic of recent debate, although the largest percentage of patients cured of the condition remains in the region of 60% [5]. It has been demonstrated that numerous factors are involved in the pathogenesis of IC. These include autoimmune phenomena [6], injury to the urothelial glycosaminoglycan layer [7], neurological discomfort and inflammatory processes [8].

Despite the publication of several meta-analyses as well as a network meta-analysis (NMA) [9, 10], these have not provided a comprehensive review of therapeutic strategies. The lack of clarity regarding the efficacy of certain therapies in helping individuals with IC, owing to the low or very low degrees of supportive evidence, was expressed in a recent Cochrane review [9]. Although the results of numerous studies can be accessed, the majority only included small populations and so the outcomes of therapy could not be accurately evaluated. The same issue applied to a further NMA, and so the results were not apposite for the current work. Thus, studies with higher sample numbers and which are specifically targeted towards this condition are required to enhance the present quality of evidence. Randomized controlled trials (RCTs) have been added by the current authors to the literature, and they have concurrently carried out a traditional pairwise meta-analysis and an NMA to offer more evidence-based conclusions.

There are numerous types of therapy available for IC, some of which are extremely complicated, and so as well as carrying out an NMA, a general meta-analysis by effect variables has also been performed. Additionally, metaregression analysis was applied to ascertain the moderator effect. The study is underpinned by the hypothesis that a high level of therapeutic success can be achieved in patients with IC using a combination of approaches; this theory could subsequently be tested in RCTs.

Methods

The systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [11, 12]. This study completed PROSPERO registration (CRD42022384024).

Data sources and literature searches

A systematic literature search was conducted in the Pub-Med, Embase, and Cochrane databases using Medical Subject Headings terms and text keywords through April 2023 (eTable 1 in the Supplement). The subject headings and text keywords included those related to the population of interest (i.e., "IC", "BPS"), intervention (relevant treatments such as "medication", "instillation", "intravesical injection", "physical therapy" and/or others), comparison ("placebo" or "control"), and outcomes of treatments: 1) individual symptoms ("pain, frequency", "urgency" and "nocturia"), 2) structured questionnaires ("interstitial cystitis problem index" [ICPI], "interstitial cystitis symptom index" [ICSI], "pelvic pain - urgency" - "frequency symptom scale" [PUF] and "functional bladder volume" [FBV]). Search terms were categorized using Boolean operators (e.g., AND, OR, NOT). Only RCTs were included in this meta-analysis. This search was conducted regardless of language or study type. Two independent researchers (SR Shim and JH Kim) identified additional studies by manually searching trial databases and reference lists.

Study selection

Study inclusion criteria were as follows: patients diagnosed with IC/BPS, interventions included relevant treatments, comparisons were specified as control or placebo, outcomes were mean differences for individual symptoms (pain, frequency, urgency and nocturia) and structured questionnaires (ICPI, ICSI, PUF and FBV) using an RCT study design. The specific study selection was described in eTable 6 in the Supplement.

Meta-analysis assessment of outcome findings and statistical analysis

The specific data extraction and calculation methods [13] were listed in eTable 6 in the Supplement. For traditional pairwise meta-analysis, the standardized mean difference (SMD) along with their 95% confidence intervals (Cls) were calculated for continuous variables. The random-effects model calculated by restricted maximum-likelihood estimator (REML) was used to obtain the pooled overall SMD and 95% CIs for outcomes [14].

Each moderator was subjected to a meta-regression analysis for continuous variables (e.g., number of patients, age and follow-up period) and categorical variables (e.g., treatments, country, cystoscopy and Hunner lesion group). To analyse potential moderators, the study estimated the variance of the true effects using a REML estimator.


For Bayesian NMA, specific graphical analysis was completed using the "gemtc" package in R software v.4.2.1 (R Foundation for Statistical Computing) [15]. The Markov chain Monte Carlo (MCMC) simulation method and surface under the cumulative ranking curve (SUCRA) [15, 16] generation used for Bayesian NMA, and the potential publication bias [17] and quality assessment [18] were described in eTable 6 in the Supplement. A two-sided *P*-value of $\leq .05$, or not containing a null value (SMD = 0) within the 95% CI was considered to be significant.

Results

Study selection

The initial search identified a total of 411 articles from different electronic databases (PubMed, n = 105; Cochrane, n = 98; Embase, n = 208). Of these, 185 studies contained overlapping data or appeared in more than one database and were therefore excluded. After screening the titles and abstracts, 119 studies were eliminated as they were trial registrations and abstracts only. Among 107 full-text articles, 37 studies were further excluded for the following reasons: not an original article type, n = 30and not an RCT design, n = 7. Finally, 70 studies met the selection criteria for qualitative analysis (eTable 2 & 3 in the Supplement) and 47 studies for quantitative synthesis (eTable 4 in the Supplement and Fig. 1).

A systematic review and meta-analysis of the 47 studies involving a total of 3,651 patients were conducted to assess the detailed differences and subject descriptions provided in eTable 4 in the Supplement. All studies were



RCTs and conducted in Western, Eastern, and Middle Eastern countries. The mean age range was 30.1 to 65.5 years, and the follow-up period ranged from one to 24 months. The specific treatments and outcomes displayed in eTable 4 in the Supplement include: 1) medication or system injection (i.e., analgesics, antidepressants, new immune modulator, old immune modulator), 2) instillation (i.e., botulinum toxin [BTX], sodium chondroitin sulfate [CS], sodium hyaluronic acid [HA]), 3) intravesical injection (i.e., BTX, RTX, anesthetics), 4) physical therapy (i.e., radiofrequency, nerve stimulation), 5) others (i.e., dietary, hydrogen-rich water, video intervention).

Outcome findings from pairwise meta-analysis

The pooled SMDs for overall pain assessment between treatments versus the control group was -0.33 (95% CI: -0.52, -0.14). The heterogeneity test produced a Higgins' I^2 was 65.5%. In the subgroup analysis by outcome measures, the SMDs were -0.22 (95% CI; -0.39, -0.06) for instillation, and -0.53 (95% CI; -0.80, -0.27) for intravesical injection. The pooled SMDs for overall urgency assessment between treatments versus the control group was -0.40 (95% CI: -0.75, -0.05). The heterogeneity test produced a Higgins' I^2 was 79.8%. In the subgroup analysis by outcome measures, the SMD of the others group was statistically significant -0.64 (95% CI; -0.97, -0.32). The pooled SMDs for overall nocturia assessment between treatments versus the control group was -0.37 (95% CI: -0.62, - 0.11). The heterogeneity test produced a Higgins' I^2 was 44.5%. In the subgroup analysis by outcome measures, there were no statistically significant groups (Fig. 2). The pooled SMDs for overall ICPI was -0.22 (95% CI: -0.37, -0.07). The heterogeneity test produced a Higgins' I² was 54.0%. In the subgroup analysis by outcome measures, the SMDs were -0.21 (95% CI; -0.38, -0.04) for instillation, and -0.63 (95% CI; -1.02, -0.28) for intravesical injection. The pooled SMDs for overall ICSI was -0.20 (95% CI: -0.32, -0.08). The heterogeneity test produced a Higgins' I² was 32.0%. In the subgroup analysis by outcome measures, the SMDs were -0.21 (95% CI; -0.42, -0.01) for medication or system injection, -0.49 (95% CI; -0.85, -0.13) for intravesical injection, and -0.39 (95% CI; -0.69, -0.08) for others. All statistical analysis results were based on clinical practice. (Fig. 3).

Outcome findings from NMA

Using a Bayesian network meta-analysis to simultaneously examine the differences in each treatment for each outcome measure, the study found that no specific treatment showed statistically significant improvement compared to the control group in all outcomes (pain, frequency, urgency, nocturia, ICPI, ICSI, PUF and FBV) (Fig. 4, and eFigure 1 to 6 in the Supplement). The consistency test showed that the direct and indirect comparison of all outcomes was consistent, so we applied the consistency model in this study (all P > 0.05). All statistical analysis results were based on clinical practice.

Moderator analysis

The study also considered the potential moderating roles of the following variables using meta-regression analysis (Table 1 and eTable 5 in the Supplement). With increasing age, a statistically significant increase was found in nocturia ($\beta = 0.063$, P = 0.005), worsening by 3.6%. With an increasing follow-up period, a statistically significant decrease in frequency ($\beta = -0.040$, P = 0.014) was found, improving by approximately 2.3%.

Publication bias

The statistical approaches for the detection of publication bias or a small-study effect are shown in eFigure 7 in the Supplement. Individual symptoms (pain, frequency, urgency and nocturia) showed visual asymmetric graphics in funnel plots, and Egger's regression also suggested publication bias (all P < .05). However, the structured questionnaires (ICPI, ICSI, PUF and FBV) showed symmetry, and Egger's regression did not support publication bias or a small-study effect (all P > 0.05).

Quality assessment

The seventy studies were evaluated using the five RoB 2.0 domains to determine the risk of bias. In D1, fortyseven studies and twenty-three were classified as "Some concerns" and "Low". In D2 & D4, one study was classified as "igh". In D3, nine studies were classified as "Some concerns". In D5, all studies were classified as "Low". Based on these evaluations, nineteen studies were classified as "Iow", fifty studies as "Some concerns" and one study (Hsieh et al. 2012) as "High" (eFigure 8 in the Supplement).

Discussion

Through our research, we have revealed for the first time that it is appropriate to try a combination of multiple treatments clinically rather than just one treatment in treating the difficult-to-overcome disease called interstitial cystitis. Even though the outcomes of the NMA were in keeping with the data published in the Cochrane review [9], the former highlighted an alternative perspective in that in comparison to a placebo, the overall effects of treatment for discomfort, nocturia, ICPI and ICSI were greater. The types of therapy applied included intravesical instillation or injection, and additional strategies, such as diet modification and hyperbaric oxygen. The meta-regression analysis demonstrated that for frequency, the longer the follow-up duration, the more




Fig. 2 Forest plots for individual symptoms of pain, frequency, urgency, and nocturia (clockwise) in pairwise meta-analysis. SMD, standardized mean difference; CI, confidence interval; PPS, pentosane polysulfate; MPD, monophosphate dehydrogenase; HA, hyaluronic acid; CS, chondroitin sulfate; HL, heparin sodium-lidocaine; BTX, botulinum toxin

improved the clinical results. Ageing was identified as a negative moderator associated with a poorer end result in nocturia. The NMA showed that in comparison to a placebo, no single therapy offered any benefit to patients with IC. However, where more than one therapeutic approach was applied, such as an adjunctive immune modulator, intravesical injection, intravesical instillation with BTX or HA, or HA and CS, or changes in diet, more positive outcomes could be anticipated which could be demonstrated in the future by RCTs.

The study NMA objective was to evaluate the effectiveness of any drug treatments available for IC. Although the underlying causes of IC remain poorly defined, there are some data to suggest that in this condition, there is an

						B.ICSI				
udy or					Std. Mean Difference	Study or Subgroup	treatment	n SMD	95% CI	Std. Mean Differe
ibgroup	treatment	n S	SMD	95% CI	IV, Random, 95% CI	Medication or System in		II OMD	55% CI	IV, Randolli, 80%
edication or System inje						Bosch et al. 2014	new_immune_modulator	21 -0.322	[-1.013; 0.368]	
osch et al. 2014	new_immune_modulator					Bosch et al. 2018	new_immune_modulator			
osch et al. 2018	new_immune_modulator					Cartledge et al. 2000	amino_acid	16 -0.404	[-1.241; 0.434]	
ster et al. 2010				.663; -0.049]		Foster et al. 2010	antidepressants		[-0.748; -0.149]	-
oubiers et al. 2021	ASP3652_100mg			.584; 0.188]		Houbiers et al. 2021	ASP3652_100mg		[-0.546; 0.218]	-
oubiers et al. 2021	ASP3652_300mg			.228; 0.495]		Houbiers et al. 2021	ASP3652_300mg		[-0.262; 0.462]	-
oubiers et al. 2021	ASP3652_600mg	96 -0.	.030 [-0	.350; 0.290]		Houbiers et al. 2021	ASP3652_600mg		[-0.381; 0.259]	+
asyan et al. 2021	PPS			.092; -0.072]		Kasyan et al. 2021	PPS		8 [-1.624; -0.552]	
ant et al. 2003	PPS	31 0.	.161 [-0	.375; 0.697]		Sant et al. 2003	PPS		[-0.212; 0.827]	+
ant et al. 2003	antihistamine	29 0.	.163 [-0	.381; 0.707]		Sant et al. 2003	antihistamine		8 [-0.431; 0.647]	
ant et al. 2003	PPS_antihistamine			.767; 0.374]		Sant et al. 2003	PPS_antihistamine		[-0.886; 0.257]	
'ang et al 2011	old_immune_modulator	39 0.	.178 [-0.	.369; 0.726]		Wang et al. 2017	new_immune_modulator			
otal (95% Cl)				283; 0.031]	•	Yang et al 2011	old_immune_modulator	39 0.170	[-0.380; 0.719]	
eterogeneity: Tau ² = 0.0153; C	chi ² = 12.63, df = 10 (P = 0.25); l	2 = 21%				Total (95% CI)	: Chi ² = 25.89, df = 12 (P = 0.01); I		[-0.417; -0.003]	•
						Heterogeneity: Tau" = 0.0749	; Chi" = 25.89, df = 12 (P = 0.01); I	r = 54%		
stillation						Instillation				
ardenas-Trowers et al. 202	1 new_immune_modulator	45 -0.	.370 [-0	.871; 0.132]			021 new_immune_modulator	45 0 134	1.0.342: 0.6091	_
huang et al. 2017	BTX_sphingomyelin			.531; 0.552]		Chuang et al. 2017	BTX_sphingomyelin			
huang et al. 2017	BTX	28 0.	.038 [-0	.515; 0.591]	_	Chuang et al. 2017	BTX_Sprinigoniyeiin		[-0.497: 0.722]	
avis et al 2008	PPS	21 -0.	.627 [-1.	.412; 0.159]		Davis et al 2008	PPS		[-3.605; -1.926]	
layer et al. 2005	BCG			.275; 0.236]	-	Mayer et al. 2005	BCG		[-0.328; 0.174]	-
ickel et al. 2008	lidocaine			.744; 0.170]		Nickel et al. 2008	lidocaine		[-0.806: 0.092]	1
ickel et al. 2010	CS			.547; 0.543]		Nickel et al. 2000	CS		[-0.301: 0.790]	
ickel et al. 2012	cs			.745; 0.210]		Nickel et al. 2012	cs		[-0.453; 0.421]	
ropert et al. 2008	BCG			.596; 0.663]		Propert et al. 2008	BCG		[-1.678; 0.186]	
oshimura et al. 2021	DMSO			.158; -0.188]		Yoshimura et al. 2021	DMSO		[-0.948; 0.075]	-
otal (95% CI)	5.000			.375; -0.035]	•	Total (95% CI)			[-0.829; 0.163]	-
	chi ² = 9.34, df = 9 (P = 0.41); 1 ² =		[-0.		-		: Chi ² = 46.4, df = 9 (P < 0.01); l ² =	81%	,	
geneny du = 0.0110; 0		1.00								
travesical injection						Intravesical injection				
uo et al 2009	BTX_200U	15 -0	607 L1	.386; 0.172]		Kuo et al 2009	BTX_200U		[-1.058; 0.416]	
uo et al 2009	BTX_100U			.343; -0.039]		Kuo et al 2009	BTX_100U		[-1.184; 0.100]	
uo et al 2016	BTX_100U			.220; 0.047]		Kuo et al 2016	BTX_100U	40 -0.579	[-1.174; 0.015]	
fotal (95% CI)	017_1000			.022; -0.237]	-	Pinto et al 2018	BTX_100U		[-1.650; 0.937]	
	0.06, df = 2 (P = 0.97); l ² = 0%	-0.	.000 [-1.	·····		Total (95% CI)		-0.488	[-0.849; -0.128]	•
everoydrieny, rau = 0, 011 =	0.00, 01 = 2 (r = 0.01), 1 = 070					Heterogeneity: Tau ² = 0; Chi ²	= 0.35, df = 3 (P = 0.95); l ² = 0%			
others										
anter et al 2016	meditation	8 0	757 1.4	.707; 0.192]		Others				
ee et al 2014	e_health			.306; 1.340]		Kanter et al 2016	meditation		[-1.306; 0.461]	
					_	Lee et al 2014	e_health	40 -0.370	[-0.849; 0.108]	
		20 1								
ee et al 2018	video_intervention	29 -1.				Lee et al 2018	video_intervention		5 [-1.217; -0.133]	
ee et al 2018 Natsumoto et al 2013		18 0.	.018 [-0	.710; 0.745]		Matsumoto et al 2013	video_intervention hydrogen_rich_water	18 0.193	[-0.580; 0.966]	
Lee et al 2018 Matsumoto et al 2013 Total (95% CI)	video_intervention hydrogen_rich_water	18 0. -0.	.018 [-0			Matsumoto et al 2013 Total (95% CI)	hydrogen_rich_water	18 0.193 -0.385		* *
Lee et al 2018 Matsumoto et al 2013 Total (95% CI) Heterogeneity: Tau ² = 0.8748; C	video_intervention hydrogen_rich_water $chi^2 = 30.99, df = 3 (P < 0.01); i^2$	18 0. -0.	.018 [-0	.710; 0.745]		Matsumoto et al 2013 Total (95% CI) Heterogeneity: Tau ² = < 0.000	hydrogen_rich_water	18 0.193 -0.385	[-0.580; 0.966]	
.ee et al 2018 Matsumoto et al 2013 Fotal (95% CI)	video_intervention hydrogen_rich_water $chi^2 = 30.99, df = 3 (P < 0.01); i^2$	18 0. -0.	.018 [-0	.710; 0.745]	-2 -1 0 1 2 Favors Treatments Favors Control	Matsumoto et al 2013 Total (95% CI)	hydrogen_rich_water	18 0.193 -0.385	[-0.580; 0.966]	-3 -2 -1 0 1 Favors Treatments Far
ee et al 2018 latsumoto et al 2013 lotal (95% CI) eterogeneity: Tau ² = 0.8748; C est for subgroup differences: C	video_intervention hydrogen_rich_water $chi^2 = 30.99, df = 3 (P < 0.01); i^2$	18 0. -0.	.018 [-0	.710; 0.745]		Matsumoto et al 2013 Total (95% CI) Heterogeneity: Tau ² = < 0.000	hydrogen_rich_water	18 0.193 -0.385	[-0.580; 0.966]	
ee et al 2018 atsumoto et al 2013 ond (95%; CI) eterogeneity: Tau ² = 0.8748; C est for subgroup differences: C C.PUF	video_intervention hydrogen_rich_water $chi^2 = 30.99, df = 3 (P < 0.01); i^2$	18 0. -0.	.018 [-0	.710; 0.745]	Favors Treatments Favors Control	Matsumoto et al 2013 Total (1955, CI) Intercomposity: Tan ² = < 0.00 Test for subgroup differences	hydrogen_rich_water	18 0.193 -0.385	[-0.580; 0.966]	Favors Treatments Fa ICSI
ee et al 2018 atsumoto et al 2013 otal (95% C1) set for subgroup differences: C C. PUF tudy or	video_intervention hydrogen_rich_water $(3h^2 = 30.90, dr = 3 (P = 0.01), l^2$ $h^2 = 5.51, dr = 3 (P = 0.14)$	18 0. -0. = 90%	.018 [-0 .311 [-1.	.710; 0.745] .295; 0.672]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (89%s): (1) Paterogenetry: Tau ² = < 0.00 Test for subgroup differences D. FBV Study or	hydrogen_tich_water 1: Chr ² = 3.28, df = 3 (P = 0.38); f ² Chr ² = 2.08, df = 3 (P = 0.58)	18 0.193 -0.385 = 8%	6 [-0.580] 0.966] 5 [-0.681; -0.080]	Favors Treatments Fa
ee et al 2018 atsumoto et al 2013 octo(16%;CI) eterogenety;Tau ² = 0.8748;C est for subgroup differences: C C. PUF tudy or ubgroup	$\label{eq:restrict} \begin{tabular}{lllllllllllllllllllllllllllllllllll$	18 0. -0.	.018 [-0 .311 [-1.	.710; 0.745]	Favors Treatments Favors Control	Matsumoto et al 2013 Total (85% CI) Heterogenety: Tau ² = < 0.00 Test for subgroup differences D. FBV Study or Subgroup	hydrogen_n(ch_water 11; Ch ² = 3.28, <i>dt</i> = 3 (P = 0.35); 1 ² Ch ² = 2.08, <i>dt</i> = 3 (P = 0.56)	18 0.193 -0.385	[-0.580; 0.966]	Favors Treatments Fa ICSI
ee et al 2018 atsumbot et al 2013 cotal (95% CI) eterogenety, Tau ² = 0.8748; C est for subgroup differences: C C. PUF tudy or ubgroup edication or System inji	$\label{eq:constraint} \begin{aligned} & video_{intervention} \\ & hydrogen_rich_water \\ & sh^2 = 30.99, \ dt = 3 \ (P = 0.01), \ l^2 \\ & h^2 = 5.51, \ dt = 3 \ (P = 0.14) \end{aligned}$ $\label{eq:constraint}$ $\label{eq:constraint} \\ & treatment \\ ection \end{aligned}$	18 0. -0. = 90%	.018 [-0. .311 [-1.	295% Ci	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (BF): CI) Peterogenetity: Tau ² = < 0.00 Test for subgroup differences D. F.B.V Study or Subgroup Medication or System In	hydrogen_tich_water 11, Ch ² = 3.26, df = 3 (P = 0.35); f ² Ch ² = 2.06, df = 3 (P = 0.56) treatment n sjection	18 0.193 -0.385 = 8%	95% CI	Favors Treatments Fa
e et al 2018 atsumoto et al 2013 tate (BSS, CI) teregenetity, Tau ² = 0.8748; C sts for subgroup differences: C C.PUF tudy or tudgroup edication or System (inj) edication or System (inj)	$\label{eq:constraint} \begin{array}{l} video_{intervention} \\ hydrogen_rich_water \\ sh^2 = 30.90, df = 3 \left(P = 0.01\right), \tilde{P}^2 \\ \tilde{n}^2 = 5.51, df = 3 \left(P = 0.14\right) \end{array}$	18 0. -0. = 90% n \$ r 21 -0	.018 [-0. .311 [-1. SMD	.710; 0.745] .295; 0.672] 95% Cl 0.829; 0.574]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (85% CI) Henegogenery: Tau ² = < 0.00 Test for subgroup differences D. FBV Study or Subgroup Medication or System II Souza et al. 2012	hydrogen_rich_water 11: Chi ² = 3.24, df = 3 (P = 0.35); i ² Chi ² = 2.08, df = 3 (P = 0.56) treatment n spection analgesics 11	18 0.193 -0.385 = 8% SMD 0.175 [-0.6	95% CI 39; 0.990]	Favors Treatments Fa
e et al 2018 astumbo et al 2013 tatemponenty, Tau ² = 0.8748; C et al (295, C) tatemponenty, Tau ² = 0.8748; C et al (2014 et al 2014 ang et al. 2017	$\label{eq:constraint} \begin{aligned} & video_{intervention} \\ & hydrogen_rich_water \\ & sh^2 = 30.99, \ dt = 3 \ (P = 0.01), \ l^2 \\ & h^2 = 5.51, \ dt = 3 \ (P = 0.14) \end{aligned}$ $\label{eq:constraint}$ $\label{eq:constraint} \\ & treatment \\ ection \end{aligned}$	18 0. -0. = 90% n S r 21 -0 r 14 -0	.018 [-0. . 311 [-1 . SMD 0.127 [-0 0.369 [-1	.710; 0.745] .295; 0.672] 95% CI 0.829; 0.574] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (95% CI) Hencogenetics Table = 0.000 Test for subgroup differences Study or Subgroup Mediciation or System In Souza et al. 2012 Van Ophown et al. 2001	hydrogen_nich_water 11; 0x ² = 3.2e, df = 3 (P = 0.50) Chr ² = 2.0e, df = 3 (P = 0.55) treatment n sigettion analgesics 11 antidepressants 25	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0	95% Cl 39; 0.990] 53; 0.941]	Favors Treatments Fa
e et al 2018 Issumoto et al 2013 Istra (205, C1) Istragenety, Tag ² + 0.8748; C4) Ist for subgroup differences: C Udy or Ubgroup differences: C Udy or Sich et al. 2014 Istragenety Istra	$\label{eq:constraint} \begin{array}{l} \mbox{video_mervention} \\ \mbox{hydrogen_mich_water} \\ \mbox{al}^{d^2} = 5.059, \mbox{al}^{d^2} = 3.(P = 0.01), \mbox{i}^2 \\ \mbox{al}^{d^2} = 5.51, \mbox{al}^{d^2} = 5.51, \mbox{al}^{d^2} = 0.14) \end{array}$	n s r 21 -0 r 14 -0 -0	.018 [-0. . 311 [-1 . SMD 0.127 [-0 0.369 [-1	.710; 0.745] .295; 0.672] 95% Cl 0.829; 0.574]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (85% CI) Pateographics Test for subgroup differences Dr. FBDV Study or Subgroup Medication or System In Souza et al. 2012 Van Ophoven et al. 2004 Total (85% CI)	hydrogen_tich_water 11: Ch ² = 3.28, df = 3 (P = 0.35); 1 ⁻ Ch ² = 2.08, df = 3 (P = 0.55) treatment n sjection analgesics 11 antidepressants 25	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0	95% Cl 39; 0.990] 53; 0.941]	Favors Treatments Fa
e et al 2018 atsumble of al 2013 tatl (8% C) temperety, Tau ² = 0.8748; C) temperety, Tau ² = 0.8748; C st for subgroup differences: C ubgroup deflication or System Injt sach et al. 2014 ang et al. 2017 tatl (8% C)	$\label{eq:constraint} \begin{array}{l} video_{intervention} \\ hydrogen_rich_water \\ sh^2 = 30.90, df = 3 \left(P = 0.01\right), \tilde{P}^2 \\ \tilde{n}^2 = 5.51, df = 3 \left(P = 0.14\right) \end{array}$	n s r 21 -0 r 14 -0 -0	.018 [-0. . 311 [-1 . SMD 0.127 [-0 0.369 [-1	.710; 0.745] .295; 0.672] 95% CI 0.829; 0.574] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (85% CI) Pateographics Test for subgroup differences Dr. FBDV Study or Subgroup Medication or System In Souza et al. 2012 Van Ophoven et al. 2004 Total (85% CI)	hydrogen_nich_water 11; 0x ² = 3.2e, df = 3 (P = 0.50) Chr ² = 2.0e, df = 3 (P = 0.55) treatment n sigettion analgesics 11 antidepressants 25	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0	95% Cl 39; 0.990] 53; 0.941]	Favors Treatments Fa
e et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; C C. PUJF tudy or Ubgroup deflection or System Injlo osch et al. 2014 ang et al. 2017 bal (95%; C1) teregenent; Tan ² = 0, Ch ² =	$\label{eq:constraint} \begin{array}{l} \mbox{video_mervention} \\ \mbox{hydrogen_mich_water} \\ \mbox{al}^{d^2} = 5.059, \mbox{al}^{d^2} = 3.(P = 0.01), \mbox{i}^2 \\ \mbox{al}^{d^2} = 5.51, \mbox{al}^{d^2} = 5.51, \mbox{al}^{d^2} = 0.14) \end{array}$	n s r 21 -0 r 14 -0 -0	.018 [-0. . 311 [-1 . SMD 0.127 [-0 0.369 [-1	.710; 0.745] .295; 0.672] 95% CI 0.829; 0.574] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (85% CI) Pateographics Test for subgroup differences Dr. FBDV Study or Subgroup Medication or System In Souza et al. 2012 Van Ophoven et al. 2004 Total (85% CI)	hydrogen_tich_water 11: Ch ² = 3.28, df = 3 (P = 0.35); 1 ⁻ Ch ² = 2.08, df = 3 (P = 0.55) treatment n sjection analgesics 11 antidepressants 25	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0	95% Cl 39; 0.990] 53; 0.941]	Favors Treatments Fa
e et al 2018 assumble of a 2013 tatemponety, Tan ² = 0.8748; C C. PUF tatly or budy or deflaction or System Ingl edication or System Ingl ang et al 2017 brat (95%; Cl) stillation	$\label{eq:constraint} \begin{array}{l} \mbox{where} \m$	18 0. -0. = 90% n 5 r 21 -0 r 14 -0 -0	.018 [-0. .311 [-1. .311 [-1. 0.127 [-0. 0.369 [-1 0.229 [-0	95% CI 0.829; 0.574] 1.194; 0.456] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (95-CI) Heterspreatry: Tay ² = < 0.00 Test for subgroup differences Study or Study or Source et al. 2012 Van Ophoven et al. 2002 Van Ophoven et al. 2004 Total (955-CI) Heterspreatry: Tay ² = 0.00 ⁴	hydrogen_sch_water 11, Ch ² = 3.2a, df = 3 (F = 0.33), f Ch ² = 2.0a, df = 3 (F = 0.55) Ch ² = 2.0a, df = 3 (F = 0.55) Indigenesis 11 antidepressants 25 = 0.41, df = 1 (F = 0.52), f ² = 0%	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0	 \$ [-0.580]; 0.966] \$ [-0.691]; -0.080] 95% C1 39; 0.990] \$ [:0.849] 	Favors Treatments Fa
ee et al 2018 atsumbor et al 2013 octol (95%, CI) eterogenetty, Tau ² = 0.8748; c est for subgroup differences: C C.PUF tudy or Udgroup fedication or System Injo och et al. 2014 vang et al. 2017 octal (95%, CI) eterogenetty, Tau ² = 0; Chi ² = wstillation	$\label{eq:constraint} \begin{array}{l} \mbox{video_mervention} \\ \mbox{hydrogen_mich_water} \\ \mbox{al}^{d^2} = 5.059, \mbox{al}^{d^2} = 3.(P = 0.01), \mbox{i}^2 \\ \mbox{al}^{d^2} = 5.51, \mbox{al}^{d^2} = 5.51, \mbox{al}^{d^2} = 0.14) \end{array}$	18 0. -0. = 90% n 5 r 21 -0 r 14 -0 -0	.018 [-0. .311 [-1. .311 [-1. 0.127 [-0. 0.369 [-1 0.229 [-0	95% CI 0.829; 0.574] 1.194; 0.456] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (1954; CI) Heterogenetity: Tau ² = < 0.000 Test for subgroup differences Discrete Constraints Subgroup Subgrou	treatment n ijection analgesics 11 antidepresants 25 = 0.41, df = 1 (P = 0.52); i' 55	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0	95% CI 39, 0.960] 39, 0.960] 53, 1.041] 59, 0.449] 60, 0.522]	Favors Treatments Fa
ee et al 2018 absumbo et al 2013 otal (195%, C1) sterogenehty, Tau ² = 0.8748; c stst for subgroup differences: C C.PUF tudy or budgroup fedication or System Injo osch et al. 2014 /ang et al. 2017 otal (195%; C1) sterogenehty, Tau ² = 0; Chi ² = stillation	$\label{eq:constraint} \begin{array}{l} \mbox{where} \m$	18 0. -0. = 90% n 5 r 21 -0 r 14 -0 -0	.018 [-0. .311 [-1. .311 [-1. 0.127 [-0. 0.369 [-1 0.229 [-0	95% CI 0.829; 0.574] 1.194; 0.456] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (BSF. CI) Retengenetity: Tau ² = < 0.002 Test for subgroup differences D. F.E.V. Study or Subgroup Medication or System in Souza et al. 2012 Van Ophown et at. 2014 Total (BS%, CI) Heterogenetity: Tau ² = 0; Chai Change et al. 2017	treatment n 1, 0x ² = 3.26, df = 3 (P = 0.33); f 0x ² = 2.06, df = 0 (P = 0.33); f cha ² = 2.06, df = 3 (P = 0.53); f 11 analogescs 11 antidepressants 25 = 0.41, df = 1 (P = 0.52); f ² = 0% 31 BTX_sphingonyelin 31 BTX 28	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0	95% CI 95% CI 39; 0,990] 39; 10,49] 60; 0,522] 60; 0,522] 60; 0,523]	Favors Treatments Fa
ee et al 2018 absumbo et al 2013 otal (195%, C1) sterogenehty, Tau ² = 0.8748; c stst for subgroup differences: C C.PUF tudy or budgroup fedication or System Injo osch et al. 2014 /ang et al. 2017 otal (195%; C1) sterogenehty, Tau ² = 0; Chi ² = stillation	$\label{eq:constraint} \begin{array}{l} \mbox{where} \m$	18 0. -0. = 90% n 5 r 21 -0 r 14 -0 -0	.018 [-0. .311 [-1. .311 [-1. 0.127 [-0. 0.369 [-1 0.229 [-0	95% CI 0.829; 0.574] 1.194; 0.456] 1.194; 0.456]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (895:61) Teterogenetity: Tau ² = < 0.002 Test for subgroup differences Budgroup Medication or System In Souza et al. 2012 Van Ophorem et al. 2004 Total (895: C1) Heterogenetity: Tau ² = 0.014 Instillation Chuang et al. 2017 Irani et al. 2004	treatment n njech 2.08, df = 3 (P = 0.33); l' chr ² = 2.08, df = 3 (P = 0.53); l' 3(P = 0.53); l' tjection analgesics 11 analgesics 12 14 e 0.41, df = 1 (P = 0.52); l ² = 0% 28 BTX 28 BG BTX 28 G	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0	95%, C1 95%, C1 39, 0.960] 39, 0.960] 30, 0.960] 60, 0.522] 60, 0.522] 60, 0.523]	Favors Treatments Fa
ee et al 2018 absumbol et al 2013 otal (89%, CI) sterogenetity: Tau ² = 0.8748; c sist for subgroup differences: C C. PUF tudy or budgroup ledication or System Infr osch et al, 2017 otal (89%, CI) sterogenetity: Tau ² = 0; Ch ² = stillation ardenas-Trowers et al, 20 thers	$\label{eq:constraint} \begin{array}{l} \mbox{where} \m$	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments Favors Control ICPI Std. Mean Difference	Matsumoto et al 2013 Total (95-CI) Hetersprecht; Tay ² = < 0.007 Test for subgroup differences Study or Study or Medication or System II Souz et al. 2012 Van Ophoven et al. 2004 Total (193-CI) Hetersprecht; Tay ² = 0.Ch/ Instillation Chuang et al. 2017 Chuang et al. 2017	treatment n treatment n updreton analgesics analgesics 11 antidepressants 25 = 0.41, of = 1 (P = 0.52); P ² = 05 31 BTX_sphingonyelin 31 BTS BGG 13	18 0.193 -0.385 - 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0 0.395 [-0.0 0.365 [-0.3 0.365 [-0.3	95% CI 95% CI 39.0390] 53.1.041] 60.0.522] 26.0.963] 46.0.052]	Favors Treatments Fa
ee et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; CH C. PUJF Utdy or deflaction or System Infl osch et al 2014 ang et al. 2014 ang et al. 2017 tata (95%; CI) tetrogenetic; Tan ² = 0; Ch ² = astillation arclenas; Charles astillation there astumoto et al. 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Control ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et al 2013 Total (895; CI) Persognametry: Tax ² = < 0.005 Test for subgroup differences Study or Subgroup Medication or System In Souza et al. 2012 Van Ophowne et al. 2007 Chuang et al. 2017 Irani et al. 2005 Nickiel et al. 2005	treatment n tipedrogen_sich_water n tipedrogen_sich_water n tipedrogen_sich_water n tipedrogen_sich_water n tipedrogen_sich_water n tipedrogen_sich_water n analgesics 11 androgenesants 28 = 0.41, df = 1 (P = 0.52); l ² = 0% 11 BTX 28 BCG 15 BCG 131 BCG 131	18 0.193 -0.385 ≥ 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0 0.365 [-0.3 0.015 [-0.2 0.365 [-0.2 0.347 [-0.1	95% CI 39, 0.960] 39, 0.960] 39, 0.960] 50, 1.041] 56, 0.862] 66, 0.862] 66, 0.863] 46, 1.076] 56, 0.2863]	Favors Treatments Fa
e et al 2018 alsumoto et al 2013 tartogenety, Tar ² = 0.8748; C C. PUF udy or alsorop delatation or System inju- sche et al. 2014 ang et al. 2017 tata (95%; CI) terrogenety; Tar ² = 0; Ch ² = attiliation arcdenas-Trowers et al. 200 heres tatumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et al 2013 Total (195% CI) Paterogenety: Tau ² = < 0.00 Test for subgroup differences Studg or Subgroup Meterogenety: Tau ² = 0.04 Total (195% CI) Heterogenety: Tau ² = 0.04 Instillation Chuang et al. 2017 Chuang et al. 2017 Linani et al 2004	treatment n treatment n uperior analgesics analgesics 11 antidepressants 25 = 0.41, of = 1 (P = 0.52); l ² = 0% 31 BTX_sphingomyelin 31 BTX_sphingomyelin 31 BCG 13 CS 49 DMSO 49	18 0.193 -0.385 - 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0 0.395 [-0.0 0.365 [-0.3 0.365 [-0.3	 [-0.580; 0.966] [-0.681; -0.080] 95% CI 39; 0.960] 53; 1.041] 56; 0.546] 66; 0.522] 66; 0.523] 46; 1.076] 46; 0.268] 45; 0.268] 	Favors Treatments Fa
e et al 2018 alsumoto et al 2013 tartogenety, Tar ² = 0.8748; C C. PUF udy or alsorop delatation or System inju- sche et al. 2014 ang et al. 2017 tata (95%; CI) terrogenety; Tar ² = 0; Ch ² = attiliation arcdenas-Trowers et al. 200 heres tatumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et a 2013 Total (95% CI) Henogenery: Tau ² ≈ 4.005 Test for subgroup differences Budgroup Matgroup	hydrogen_tich_water tt: Dr/m = 3.2a, dt = 3 (P = 0.3b); tt: Dr/m = 3.2a, dt = 3 (P = 0.5b); tt: Dr/m = 3.2a, dt = 3 (P = 0.5b); tt: Dr/m = 3.2b; analogesics 11 analogesics 11 analogenerssants 25 = 0.41, df = 1 (P = 0.52); t ² = 0% 31 BTX_sphingomyelin 31 BCG 15 BCG 15 BCG 15 BCG 13 DMSO 49	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0 0.365 [-0.3 0.365 [-0.3] [-0.4] [-	 [-0.580; 0.966] [-0.681; -0.080] 95% CI 39; 0.960] 53; 1.041] 56; 0.546] 66; 0.522] 66; 0.523] 46; 1.076] 46; 0.268] 45; 0.268] 	Favors Treatments Fa
ee et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; CH C. PUJF Utdy or deflaction or System Infl osch et al 2014 ang et al. 2014 ang et al. 2017 tata (95%; CI) tetrogenetic; Tan ² = 0; Ch ² = astillation arclenas; Charles astillation there astumoto et al. 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et a 2013 Total (95% CI) Henogenery: Tau ² ≈ 4.005 Test for subgroup differences Budgroup Matgroup	treatment n treatment n uperior analgesics analgesics 11 antidepressants 25 = 0.41, of = 1 (P = 0.52); l ² = 0% 31 BTX_sphingomyelin 31 BTX_sphingomyelin 31 BCG 13 CS 49 DMSO 49	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0 0.365 [-0.3 0.365 [-0.3] [-0.4] [-	 [-0.580; 0.966] [-0.681; -0.080] 95% CI 39; 0.960] 53; 1.041] 56; 0.546] 66; 0.522] 66; 0.523] 46; 1.076] 46; 0.268] 45; 0.268] 	Favors Treatments Fa
e et al 2018 alsumoto et al 2013 tartogenety, Tar ² = 0.8748; C C. PUF udy or alsorop delatation or System inju- sche et al. 2014 ang et al. 2017 tata (95%; CI) terrogenety; Tar ² = 0; Ch ² = attiliation arcdenas-Trowers et al. 200 heres tatumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et a 2013 Total (95% CI) Henogenery: Tau ² ≈ 4.005 Test for subgroup differences Budgroup Matgroup	hydrogen_tich_water tt: Dr/m = 3.2a, dt = 3 (P = 0.3b); tt: Dr/m = 3.2a, dt = 3 (P = 0.5b); tt: Dr/m = 3.2a, dt = 3 (P = 0.5b); tt: Dr/m = 3.2b; analogesics 11 analogesics 11 analogenerssants 25 = 0.41, df = 1 (P = 0.52); t ² = 0% 31 BTX_sphingomyelin 31 BCG 15 BCG 15 BCG 15 BCG 13 DMSO 49	18 0.193 -0.385 = 8% SMD 0.175 [-0.6 0.494 [-0.0 0.395 [-0.0 0.395 [-0.0 0.365 [-0.3 0.365 [-0.3] [-0.4] [-	 [-0.580; 0.966] [-0.681; -0.080] 95% CI 39; 0.960] 53; 1.041] 56; 0.546] 66; 0.522] 66; 0.523] 46; 1.076] 46; 0.268] 45; 0.268] 	Favors Treatments Fa
ee et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; CH C. PUJF Utdy or deflaction or System Infl osch et al 2014 ang et al. 2014 ang et al. 2017 tata (95%; CI) tetrogenetic; Tan ² = 0; Ch ² = astillation arclenas; Charles astillation there astumoto et al. 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Maisumoto et a 1013 Total (1954, CI) Head (1954, CI) Test for subgroup differences D. F.F.U B. C.F.U B. C.F.U Marching (1954, CI) Marching (1954, CI)	hydrogen_tich_water 11, Car ² = 3.2, dt = 1 (P = 0.33); l ² Car ² = 2.08, dt = 3 (P = 0.53); l ² Car ² = 2.08, dt = 3 (P = 0.53); l ² ijoction analgesics 11 analgesics 12 e0.41, dt = 1 (P = 0.52); l ² = 010 BTX 28 BGG 131 BTX 26 BGG 131 CG 149 DMSO 49	18 0.132 -0.385 SMD 0.175 [-0.6 0.036 [-0.0 0.036 [-0.0 0.036 [-0.0 0.036 [-0.0 0.036 [-0.0 0.036 [-0.0 0.036 [-0.0 0.036 [-0.0] 0.036	95% CI 95% CI 39.0.960] 39.0.960] 60.0.522] 60.0.522] 60.0.522] 60.0.522] 60.0.522] 99.1.044] 99.1.048]	Favors Treatments Fa
ee et al 2018 atsumbor et al 2013 octol (95%, CI) eterogenetty, Tau ² = 0.8748; c est for subgroup differences: C C.PUF tudy or Udgroup fedication or System Injo och et al. 2014 vang et al. 2017 octal (95%, CI) eterogenetty, Tau ² = 0; Chi ² = wstillation	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et al 2013 Total (1955; CI) Menogenety; Tau ² = < 0.000 Test for subgroup differences D. F.F.V Study or Subgroup Metrogenety: Tau ² = <0.001 Total (1955; CI) Heterogenety: Tau ² = <0.001 Total (1955; CI) Mayor et al. 2005 Nickan et al. 2001 Yoshimura et al. 2005 Nickan et al. 2001 Yoshimura et al. 2001 Yoshimura et al. 2005 Nickan et al. 2001 Yoshimura et al. 2005 Nickan et al. 2001 Merogenety; Tau ² = <0.006	hydrogen_nch_water : 11, Ch ² = 3.26, df = 3 (P = 0.33); (Ch ² = 2.08, df = 3 (P = 0.53); (Ch ² = 2.08, df = 3 (P = 0.53); (Ch ² = 2.08, df = 3 (P = 0.53); (11 antidepressants 15 = 0.41, df = 1 (P = 0.52); (= 0.41, df = 1 (P = 0.52); (BTX_sphingomyelin 31 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphingomyelin 32 BTX_sphin	18 0.132 -0.385 SMD 0.175 [-0.66 0.494 [-0.0 0.395 [-0.0 0.031 [-0.4 0.478 [-0.0 0.031 [-0.4 0.478 [-0.0 0.395 [-0.0 0.395 [-0.0 0.395 [-0.0 0.395 [-0.0 0.247 [-0.1 0.250 [-0.0 0.247 [-0.1 0.250 [-0.0 0.250 [-0.0] [-0.0 0.250 [-0.0] [-0.	 [-0.690; -0.966] [-0.691; -0.080] 95% CI 99% CI 99% C3 1.041] 99, 0.460] 60, 0.522] 60, 0.853] 40, 1.076] 50, 0.286] 99; 1.048] 99; 1.048] 43, 1.581] 	Favors Treatments Fa
ee et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; CH C. PUJF Utdy or deflaction or System Inflo osch et al 2014 ang et al. 2014 ang et al. 2017 tata (95%; CI) tetrogenetic; Tan ² = 0; Ch ² = astillation arclenas; Charles	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et a 1013 Total (1995, CI) Hater (1995, CI) Test for subgroup differences D. FEV Study of Study of Stud	hydrogen_tich_water 11, Diff = 3.26, df = 3 (P = 0.33); l Chr ² = 2.08, df = 3 (P = 0.53); l Chr ² = 2.08, df = 3 (P = 0.53); l analgesics 11 andidgesics 11 andidgesics 11 andidgesics 11 BTX 28 BGG 13 BTX 28 DGG 13 BGG 14 DMSO 49 L; Chr ² = 8.74, df = 5 (P = 0.12); l ² BTX_200U 15 BTX_200U 15	18 0.023 -336 -356 -3	95% C1 39, 0.990] 39, 0.990] 30, 0.990] 40, 0.449] 40, 0.449] 40, 0.452] 40, 0.453] 41, 1.048] 43, 1.581] 81, 0.044]	Favors Treatments Fa
e et al 2018 alsumoto et al 2013 tartogenety, Tar ² = 0.8748; C C. PUF udy or alsorop delatation or System inju- sche et al. 2014 ang et al. 2017 tata (95%; CI) terrogenety; Tar ² = 0; Ch ² = attiliation arcdenas-Trowers et al. 200 heres tatumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et al 2013 Total (95-CI) Heterogenety: Tay ² = < 0.002 Test for subgroup differences Study or Study or Study or Study or Medication or System II Source al. 2012 Van Ophoven et al. 2004 Total (95% CI) Heterogenety: Tay ² = 0.026 Instillation Chuang et al. 2017 Chuang	hydrogen_tick_weter 11, Cirk ² = 3.26, df = 3 (P = 0.35); (Cirk ² = 2.06, df = 3 (P = 0.53); (Cirk ² = 2.06, df = 3 (P = 0.53); (Cirk ² = 2.06, df = 3 (P = 0.52); (Cirk ² = 0.11); (Cirk ² = 0.11); (Cirk ² = 0.11); (Cirk ² = 0.12); (C	18 0.032 -335 -355 SMD 0.175 [-0.04 0.036 [-0.0 0.036 [-0.0 0.0 0.036 [-0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	95% CI 95% CI 39, 0.960] 39, 0.960] 33, 1.041] 36, 0.849] 60, 0.522] 60, 0.823] 45, 1.041] 45, 0.849] 41, 1.041] 43, 1.041] 43, 1.041]	Favors Treatments Fa
ee et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; CH C. PUJF Utdy or deflaction or System Inflo osch et al 2014 ang et al. 2014 ang et al. 2017 tata (95%; CI) tetrogenetic; Tan ² = 0; Ch ² = astillation arclenas; Charles	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et al 2013 Total (895; CI) Menogenetity: Tau ² ≈ 0.005 Test for subgroup differences D. F.F.V Study of Subgroup Magnetisation or System In Souza et al. 2012 Van Ophownet et al. 2003 Chuang et al. 2017 Irani et al. 2004 Mayer et al. 2005 Nickie et al. 2001 Vashimura et al. 2021 Total (895; CI) Heterogenetity: Tau ² = 0.020 Nickie et al. 2021 Yoshimura et al. 2021 Total (195; CI) Heterogenetity: Tau ² = 0.020 Intravesical Injection Kuo et al 2009 Kuo et al. 2009	hydrogen_tich_water 10 cm ² = 3.26, dt = 3 (P = 0.33); f. 10 cm ² = 2.08, dt = 3 (P = 0.53); f. 10 cm ² = 2.08, dt = 3 (P = 0.53); f. 10 cm ² = 3.04, dt = 3 (P = 0.52); f. 11 andicepresents 21 andicepresents 21 andicepresents 23 CG 24 C, sphingomyelin 31 BTX 26 CG 21 BTX 23 CG 24 CG 25 CG 26 CG 27 CG 28 CG 29 CG 20 CG 20 CG 20 CG 20 CG 21 Cm ² 22 CM 23 CG 24 CG 25 CM ² 26 CG 27 CM ² 28 CG 29 CG 20 CG 20 CG 21 CM ² 21 CM ² 22 CM ² 23 CG 24 CG 25 CM ² 26 CG 27 CM ²	18 0.023 -335 -335 SMD 0.175 [0.6 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.355 [0.0 0.494 [0.0] 0.4	95% CI 95% CI 39, 0.960] 39, 0.960] 33, 1.041] 36, 0.849] 60, 0.522] 60, 0.823] 45, 1.041] 45, 0.849] 41, 1.041] 43, 1.041] 43, 1.041]	Favors Treatments Fa
ee et al 2018 atsumoto et al 2013 otal (85% CI) sterogenety, Tau ² = 0.8748; c sets for subgroup differences: C C.PUF tudy or ubgroup declatation or System Injt osch et al. 2014 orang et al. 2017 otal (95% CI) sterogenety. Tau ² = 0; Chi ² = sstillation ardenas-Trowers et al. 20 thers atsumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Matsumoto et al 2013 Total (895; CI) Menogenetity: Tau ² ≈ 0.005 Test for subgroup differences D. F.F.V Study of Subgroup Magnetisation or System In Souza et al. 2012 Van Ophownet et al. 2003 Chuang et al. 2017 Irani et al. 2004 Mayer et al. 2005 Nickie et al. 2001 Vashimura et al. 2021 Total (895; CI) Heterogenetity: Tau ² = 0.020 Nickie et al. 2021 Yoshimura et al. 2021 Total (195; CI) Heterogenetity: Tau ² = 0.020 Intravesical Injection Kuo et al 2009 Kuo et al. 2009	hydrogen_tick_weter 11, Dirk = 3.26, dt = 3 (P = 0.35); (Chr ² = 2.06, dt = 3 (P = 0.53); (Chr ² = 2.06, dt = 3 (P = 0.53); (Chr ² = 2.06, dt = 3 (P = 0.52); (Chr ² = 0.11, dt = 1 (P = 0.52); (Chr ² = 0.52	18 0.023 -335 -335 SMD 0.175 [0.6 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.355 [0.0 0.494 [0.0] 0.4	95% CI 95% CI 39, 0.960] 39, 0.960] 33, 1.041] 36, 0.849] 60, 0.522] 60, 0.823] 45, 1.041] 45, 0.849] 41, 1.041] 43, 1.041] 43, 1.041]	Favors Treatments Fa
ee et al 2018 atsumoto et al 2013 otal (85% CI) sterogenety, Tau ² = 0.8748; c sets for subgroup differences: C C.PUF tudy or ubgroup declatation or System Injt osch et al. 2014 orang et al. 2017 otal (95% CI) sterogenety. Tau ² = 0; Chi ² = sstillation ardenas-Trowers et al. 20 thers atsumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Adasumoto et al 2013 Total (1995; CI) Hondowy, Tau ² = 0.0005 Test for subgroup differences D. F.D.C. B. Marge of al <i>D. Marge of al</i> <i>D. Marge of al <i>D. Marge of al</i> <i>D. Marge of al <i>D. Marge of al</i> <i>D</i></i></i>	hydrogen_tich_water 10 cm ² = 3.26, dt = 3 (P = 0.33); f. 10 cm ² = 2.08, dt = 3 (P = 0.53); f. 10 cm ² = 2.08, dt = 3 (P = 0.53); f. 10 cm ² = 3.04, dt = 3 (P = 0.52); f. 11 and/depresants 25 20.04, dt = 1 (P = 0.52); f. 11 and/depresants 26 27. 28, dt = 1 (P = 0.52); f. 12 BTX 28 29.04, dt = 1 (P = 0.52); f. 11 and/depresants 21 BTX 28 29.05 29.06 20.07 20.08 20.09 </td <td>18 0.023 -335 -335 SMD 0.175 [0.6 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.355 [0.0 0.494 [0.0] 0.4</td> <td>95% CI 95% CI 39, 0.960] 39, 0.960] 33, 1.041] 36, 0.849] 60, 0.522] 60, 0.823] 45, 1.041] 45, 0.849] 41, 1.041] 43, 1.041] 43, 1.041]</td> <td>Favors Treatments Fa</td>	18 0.023 -335 -335 SMD 0.175 [0.6 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.494 [0.0 0.355 [0.0 0.494 [0.0] 0.4	95% CI 95% CI 39, 0.960] 39, 0.960] 33, 1.041] 36, 0.849] 60, 0.522] 60, 0.823] 45, 1.041] 45, 0.849] 41, 1.041] 43, 1.041] 43, 1.041]	Favors Treatments Fa
ee et al 2018 astumbo et al 2013 tatemponent, Tan ² = 0.8748; CH C. PUJF Utdy or deflaction or System Inflo osch et al 2014 ang et al. 2014 ang et al. 2017 tata (95%; CI) tetrogenetic; Tan ² = 0; Ch ² = astillation arclenas; Charles	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Maisumoto et al 2013 Total (1995; CI) Menogenety: Tau ² = < < Cherner De L'EDU De L'EDU De L'EDU Maige ottal Maige ot	hydrogen_tick_water 11: On ² = 3.26, df = 3 (P = 0.35); Cha ² = 2.06, df = 3 (P = 0.55); Cha ² = 2.06, df = 3 (P = 0.55); Teatment n Jection 11 antidepressants 25 e0.41, df = 1 (P = 0.52); 24 BTX_sphingomyelin 31 BTX_sphingomyelin 31 BCG 15 BCG 15 BCG 15 BCG 16 DNS 49 DMS 16 BTX_100U 16 BTX_100U 16 BTX_100U 16 BTX_100U 16 BTX_10U 16	10 0.019 -0.355 -0.3	95% CI 95% CI 39, 0.990] 33, 1.041] 58, 0.849] 60; 0.522] 26, 0.849] 40; 1.041] 40; 0.649] 41; 1.581] 42; 1.581] 43; 1.581] 43; 0.694] 40; 0.041] 39; 0.047]	Favors Treatments Fa
e et al 2018 alsumoto et al 2013 tartogenety, Tar ² = 0.8748; C C. PUF udy or alsorop delatation or System inju- sche et al. 2014 ang et al. 2017 tata (95%; CI) terrogenety; Tar ² = 0; Ch ² = attiliation arcdenas-Trowers et al. 200 heres tatumoto et al 2013	video_intervention hydrogen_inch_water $as^2 = 30.99, dt = 3 (P = 0.01); l^2$ $as^2 = 5.51, dt = 3 (P = 0.14)$ testment testment new_immune_modulato 0.19, dt = 1 (P = 0.66); l^2 = 0% 21 new_immune_modulato hydrogen_rich_water	n \$ -0, -0, -0, -0, -0, -0, -0, -0, -0, -0,	.018 [-0. .311 [-1. .53MD [-1. .339 [-1. .229 [-0.	710; 0.745] 295; 0.672] 95% CI 0.829; 0.574] 1.94; 0.456] 7.763; 0.306]	Favors Treatments ICPI Std. Mean Difference IV, Random, 95% CI	Maisumoto et a 2013 Total (1955, CI) Hotogony, Tau ² = < 0.005 Test for subgroup differences Study or Subgroup Medication or System in Soura et al. 2017 Oracia (1955, CI) Hotogony et al. 2017 Chuang et al. 2017 Chuang et al. 2017 Krai et al 2004 Nickel et al. 2012 Yoshimura et al. 2021 Total (1955, CI) Hotogonesty, Tau ² = 0.506 Intravesical injection Kuo et al 2009 Kiso et al 2016 Total (1955, CI) Hotogonesty, Tau ² = 0.105	hydrogen_tich_water 10 cm ² = 3.26, dt = 3 (P = 0.33); f. 10 cm ² = 2.08, dt = 3 (P = 0.53); f. 10 cm ² = 2.08, dt = 3 (P = 0.53); f. 10 cm ² = 3.04, dt = 3 (P = 0.52); f. 11 and/depresants 25 20.04, dt = 1 (P = 0.52); f. 11 and/depresants 26 27. 28, dt = 1 (P = 0.52); f. 12 BTX 28 29.04, dt = 1 (P = 0.52); f. 11 and/depresants 21 BTX 28 29.05 29.06 20.07 20.08 20.09 </td <td>10 0.019 -0.355 -0.3</td> <td>95% CI 95% CI 39, 0.990] 33, 1.041] 58, 0.849] 60; 0.522] 26, 0.849] 40; 1.041] 40; 0.649] 41; 1.581] 42; 1.581] 43; 1.581] 43; 0.694] 40; 0.041] 39; 0.047]</td> <td>Favors Treatments Fa</td>	10 0.019 -0.355 -0.3	95% CI 95% CI 39, 0.990] 33, 1.041] 58, 0.849] 60; 0.522] 26, 0.849] 40; 1.041] 40; 0.649] 41; 1.581] 42; 1.581] 43; 1.581] 43; 0.694] 40; 0.041] 39; 0.047]	Favors Treatments Fa

Fig. 3 Forest plots for structured questionnaires of ICPI, ICSI, PUF, and FBV (clockwise) in pairwise meta-analysis. SMD, standardized mean difference; CI, confidence interval; PPS, pentosane polysulfate; MPD, monophosphate dehydrogenase; HA, hyaluronic acid; CS, chondroitin sulfate; HL, heparin sodium-lidocaine; BTX, botulinum toxin; ICPI, interstitial cystitis problem index; ICSI, interstitial cystitis symptom index; PUF, pelvic pain – urgency - frequency symptom scale; FBV, functional bladder volume

aberrant immune response. Thus, controlling the intravesical immune response could be a potential therapeutic strategy.

Injection into the bladder was also categorized during this work. Out of a range of possible treatments, intravesical instillation or injection was shown to be an efficacious therapy in pairwise meta-analysis. Recommendations published by the American Urological Association (AUA) state that this procedure should be performed following the failure of first-line approaches and alongside oral treatments and physiotherapy [3].




Fig. 4 Network plots, forest plots, and SUCRA values of pain in network meta-analysis

Since IC is a chronic condition, therapy and monitoring should be carried out over the long term [19]. Current therapeutic options may not offer a cure; however, in a number of patients, there may be spontaneous recovery, ultimately leading to complete relief from symptoms [3, 19]. An adverse prognostic factor for IC is age. Additionally, increased frequencies of diabetes mellitus, high blood pressure, kidney pathologies, coronary artery disease and raised serum lipids were identified [20]. Psychological symptoms were also demonstrated to be more common in this cohort, with anxiety and depression recognized in 14–52% and 16–70% of patients with IC, respectively [21]. Frequent monitoring and therapy were observed over the preceding five years in 76.3% of patients studied by Yeh et al. [22]. This group had a higher prevalence of chronic pathologies, which could impact the ongoing degree of IC. The majority of individuals who were under frequent review and who had been offered a range of therapies continued to present with bladder discomfort symptoms and were seeking novel therapeutic options. Those who no longer attended review appointments during the preceding five years had been less symptomatic following their early therapy. The current meta-regression analysis demonstrated that the more prolonged the follow-up period, the more likely frequency was to improve. Advancing years were associated

Wariablec							(500	orgency					52	Nocturia				
Valiables	k β	SMD) 95% CI		d	k	β	SMD	95% CI		Ρ	k	β	SMD	95% CI		р	×	β	SMD	95% CI		d
No. of total patients	27 0.004	4	0.000	0.009	0.08	27	0.003		-0.002	0.008	0.21	14	0.008		-0.002	0.019	0.10	6	0.025		-0.004	0.053	0.09
Age	25 0.010	0	-0.022	2 0.041	0.56	24	0.007		-0.022	0.036	0.63	13	-0.058		-0.136	0.019	0.14	7	0.063		0.019	0.107	0.005
Follow up period (month)	26 -0.027	27	-0.076	6 0.022	0.28	27	-0.040		-0.071	-0.008	0.014	13	-0.030		-0.154	0.094	0.63	6	-0.037		-0.075	0.001	0.06
Treatment					0.09						0.27						0.96						0.50
Medication or system injec- tion	~	-0.2	-0.278 -0.662	2 0.066		10		-0.012	-0.253	0.230		~		-0.478	-1.057	0.102		2		-0.177	-0.813	0.458	
Instillation	∞	-0.314	14 -0.639	9 0.011		11		-0.282	-0.531	-0.034		m		-0.213	-1.132	0.706		4		-0.628	-1.127	-0.129	
Intravesical injection	8	-0.556	56 -0.888	8 -0.224	4	Ŝ		-0.264	-0.650	0.122		-		-0.314	-1.790	1.161		ŝ		-0.305	-0.815	0.205	
Physical therapy	-	-0.66	-0.660 -1.529	9 0.208																			
Others	e	0.336	6 -0.217	7 0.888		-		0.397	-0.559	1.352		c		-0.523	-1.420	0.373							
Country					0.18						0.14						0.38						0.24
Western	17	-0.38z	3z -0.612	2 -0.149	6	19		-0.079	-0.237	0.080		12		-0.332	-0.713	0.049		4		-0.482	-0.884	-0.079	
Eastern	6	-0.146	46 -0.471	1 0.179	-	2		-0.228	-0.512	0.056		2		-0.767	-1.667	0.134		4		-0.191	-0.534	0.152	
Middle East	-	-1.1	-1.151 -2.276	6 -0.025	2	-		-0.958	-1.882	-0.034								-		-0.933	-1.823	-0.043	
Cystoscopy					0.49						0.92						0.010	0					
Yes	18	-0.3	-0.376 -0.614	4 -0.139	6	22		-0.146	-0.321	0.028		S		0.065	-0.365	0.495							
No	6	-0.2	-0.235 -0.562	2 0.091		5		-0.168	-0.544	0.208		6		-0.685	-1.059	-0.311	_						
Hunner lesion					0.65						0.68						0.104	.+					0.36
HL+/HL-	9	-0.477	77 -0.912	2 -0.041	. 	10		-0.118	-0.393	0.156		m		0.196	-0.441	0.832		m		-0.644	-1.108	-0.179	
HL-	00	-0.3	-0.371 -0.724	4 -0.018	00	S		-0.326	-0.737	0.084		, -		-0.314	-1.439	0.810		m		-0.278	-0.705	0.148	
N/A	13	-0.2	-0.242 -0.520	0.036		12		-0.13	-0.39	0.13		10		-0.62	-1.008	-0.221		m		-0.23	-0.62	0.17	

 Table 1
 Effects of moderators for interstitial cystitis in pairwise meta-analysis

with poorer clinical endpoints, e.g. nocturia; in general, each additional year of age was associated with a 3.4% deterioration in symptom score.

Although a single treatment study has been reported that BTX is effective in pain relief and that PPS helps improve subjective symptoms in patients [23, 24], the strength of the current NMA is that a de novo combination of therapy is proposed. Despite the lack of statistical evidence for the efficacy of each therapy alone in comparison to a placebo, the therapy with the highest rank for its modality was indicated by the SUCRA ranking analysis. Therapeutic combinations which are anticipated include the use of an immune moderator, injections or instillations into the bladder, e.g. with BTX, HA, or HA and CS, and diet modification.

Immune cells liberate tumor necrosis factor-alpha (TNF- α), a proinflammatory cytokine that has been implicated in the inflammatory responses associated with IC. In urothelial cells from the bladder of individuals with ulcerative IC, amplified expression of TNF- α has been observed. Additionally, serum TNF- α titers, as well as levels of additional proinflammatory cytokines, are higher in patients with IC than in control subjects. These data suggest that in addition to the activation of mast cells, these cytokines are key inflammatory mediators in the disease processes underlying IC [25].

In vivo models of autoimmune cystitis have been used to experimentally show that inhibition of TNF- α diminishes inflammation within the bladder by disrupting the triggering of mast cells [26–28]. In this context, vesical inflammation related to IC and the associated symptoms could be relieved by TNF- α inhibition and suppression of mast cell activation using agents that oppose the actions of TNF- α , e.g. adalimumab and certolizumab pegol. Clinical endpoints were enhanced following therapy with adalimumab in individuals with a moderate to severe degree of discomfort from IC [29]. However, as the placebo effect was significant, a positive proof of concept with respect to adalimumab could not be demonstrated. A further study documented that the use of certolizumab pegol in female subjects with moderate to severe unremitting IC offered greater symptom relief than a placebo [30].

In the course of development, nerve growth factor (NGF) is a key requisite for sensory and sympathetic nerve cell survival. It has also been determined that NGF is a peripheral mediator in a number of inflammatory disorders associated with pain [31]. As a humanized monoclonal antibody against NGF, tanezumab has a high affinity and specificity for bonding with NGF, thus blocking the mediator from engaging with nociceptive nerve cell receptors. The latter comprises the high- and low-affinity receptors, tropomyosin-related kinase A

and p75 [32]. Following the use of tanezumab, a clinical trial reported an improvement in pain scores as well as enhanced function and overall evaluation outcomes in individuals with chronic painful disorders, not including IC [33–35]. The initial effectiveness of pain relief following pain therapy in IC was documented by Evans et al. [36], but these data were too ambiguous to be incorporated within the current meta-analysis or NMA.

Fulranumab is a human recombinant monoclonal antibody and a powerful human NGF inhibitor. A positive dose effect has been demonstrated in painful disorders, including the neuropathy associated with diabetes. Additionally, mixed data regarding its efficacy in comparison with a placebo have been presented. In patients with osteoarthritic symptoms, fulranumab demonstrated greater efficacy than an opiate, although, in low back pain, no benefit over a placebo was seen [32]. A study by Wang et al. [37] failed to show any positive effects from one dose, but the sample size was restricted and the study had insufficient statistical power. The clinical observations from these studies suggest that it would be valuable to carry out a clinical study in larger or more selected populations to establish whether fulranumab would be effective as a treatment for the refractory pain experienced by patients with IC. Additional possible treatment strategies include options from complementary and alternative medicine. These include behavioural and physical therapies approaches to ameliorate stress and modification of the diet [4, 6]. In patients who were symptomatic with IC, an intense and systematic alteration of the diet was associated with symptom relief within three months; this benefit continued for a minimum of 12 months [38].

There are several limitations associated with this study. Firstly, despite the numerous studies encompassed, there is a surplus of specific therapeutic strategies and the study populations for the individual approaches are small. Secondly, the only first-line therapy evaluated was diet modification. AUA guidelines suggest that patient education, patient self-efficacy, behavioural changes and stress reduction should be first-line therapies in individuals with IC [3]. Finally, the large number of therapeutic possibilities evaluated precluded their concurrent analysis in the NMA.

Conclusions

In patients with IC, therapy is not straightforward. The current work has led to the recognition of a therapeutic combination for this condition that could be anticipated to have a positive clinical outcome. It was established that ongoing therapy is of value, and that the efficacy of treatments is diminished in individuals of advancing years. Additional RCTs are required to ascertain the efficacy of combined therapeutic approaches, such as immunomodulatory compounds, intravesical injection or instillation with BTX or HA, or HA and CS and diet modification.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12894-024-01485-w.

Supplementary Material 1.

Authors' contributions

Study concept and design: Shim SR and Kim JH; Data acquisition and statistical analyses: Park JJ, Lee EJ, Kim KT, Chun J, Lee SR & Shim SR; Interpretation of data: All authors; Drafting of manuscript: Kim JH, Lee EJ, Shim SR, & Park JJ; Critical revision of manuscript for important intellectual content: All authors; Supervision: Shim SR, Kim JH, & Park JJ. Kim JH and Park JJ are co-first authors. Shim SR had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This work was supported by Soonchunhyang University Research Fund. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Availability of data and materials

Data are publicly available. The data supporting this study's findings are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The systematic review and meta-analysis was registered in the PROSPERO database (registration number CRD42022384024).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, 59 Daesagwan-ro, Yongsangu, Seoul 04401, Republic of Korea. ²Department of Urology, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea. ³Department of Radiology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea. ⁴Cranbrook Kingswood Upper School, Bloomfield Hills, Michigan, United States. ⁵Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, United States. ⁶Department of Biomedical Informatics, College of Medicine, Konyang University, 158 Gwanjeodong-ro, Seo-gu, Daejeon 35365, Republic of Korea. ⁷Konyang Medical data Research group-KYMERA, Konyang University Hospital, Daejeon, Republic of Korea.

Received: 12 November 2023 Accepted: 16 April 2024 Published online: 24 April 2024

References

 Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation

- Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–70.
- Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.
- Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018;122(5):729–43.
- Pinto RA, Costa D, Morgado A, Pereira P, Charrua A, Silva J, Cruz F. Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind. Placebo Controlled Trial J Urol. 2018;199(4):998–1003.
- Ogawa T, Ishizuka O, Ueda T, Tyagi P, Chancellor MB, Yoshimura N. Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. Expert Rev Clin Pharmacol. 2018;11(5):495–505.
- Wyndaele JJJ, Riedl C, Taneja R, Lovász S, Ueda T, Cervigni M. GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2019;38(2):535–44.
- Wammack R, Remzi M, Seitz C, Djavan B, Marberger M. Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur Urol. 2002;41(6):596–600. discussion 601.
- Imamura M, Scott NW, Wallace SA, Ogah JA, Ford AA, Dubos YA, Brazzelli M. Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. Cochrane Database Syst Rev. 2020;7(7):Cd013325.
- Liu S, Zhang C, Peng L, Lu Y, Luo D. Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials. Int Urogynecol J. 2021;32(5):1061–71.
- Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
- Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, Kuss O, Higgins JP, Langan D, Salanti G. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55–79.
- Shim SR, Kim SJ, Lee J, Rücker G. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013.
- 16. Salanti G, Ades AE, loannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–71.
- 17. Shim SR, Kim SJ. Intervention meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019008.
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:I4898.
- Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007;69(4 Suppl):34–40.
- 20. Wu C-Y, Chen IH, Tong Y-C. Long-term treatment outcomes in patients with interstitial cystitis/painful bladder syndrome: 10-year experience in NCKUH. Urological Science. 2013;24(1):10–3.
- McKernan LC, Walsh CG, Reynolds WS, Crofford LJ, Dmochowski RR, Williams DA. Psychosocial co-morbidities in Interstitial Cystitis/Bladder Pain syndrome (IC/BPS): A systematic review. Neurourol Urodyn. 2018;37(3):926–41.
- 22. Yeh HL, Jhang JF, Kuo YC, Kuo HC. Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome

with or without regular follow-up and treatment. Neurourol Urodyn. 2019;38(7):1985–93.

- 23. Grigoryan B, Kasyan G, Pivazyan L, Pushkar D. Pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis with Hunner's lesions or glomerulations: systematic review and meta-analysis. Ther Adv Urol. 2022;14:17562872221102808.
- Panunzio A, Tafuri A, Mazzucato G, Cerrato C, Orlando R, Pagliarulo V, Antonelli A, Cerruto MA. Botulinum Toxin-A Injection in Chronic Pelvic Pain Syndrome Treatment: A Systematic Review and Pooled Meta-Analysis. Toxins (Basel). 2022;14(1):25. https://doi.org/10.3390/toxins14010025.
- Jiang YH, Peng CH, Liu HT, Kuo HC. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One. 2013;8(10):e76779.
- Batler RA, Sengupta S, Forrestal SG, Schaeffer AJ, Klumpp DJ. Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-alpha. J Urol. 2002;168(2):819–25.
- Boucher W, Kempuraj D, Cao J, Papaliodis D, Theoharides TC. Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation. J Urol. 2007;177(3):1186–90.
- Gonzalez RR, Fong T, Belmar N, Saban M, Felsen D, Te A. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol. 2005;173(2):630–4.
- Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191(1):77–82.
- Bosch PC. A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. Eur Urol. 2018;74(5):623–30.
- Dmitrieva N, Shelton D, Rice AS, McMahon SB. The role of nerve growth factor in a model of visceral inflammation. Neuroscience. 1997;78(2):449–59.
- Mykoniatis I, Tsiakaras S, Samarinas M, Anastasiadis A, Symeonidis EN, Sountoulides P. Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis. Biologics. 2022;16:47–55.
- Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13(8):790–8.
- Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011;152(10):2248–58.
- 35. Zhao D, Luo MH, Pan JK, Zeng LF, Liang GH, Han YH, Liu J, Yang WY. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2022;14:1759720x211067639.
- Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–21.
- Wang H, Russell LJ, Kelly KM, Wang S, Thipphawong J. Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. BMC Urol. 2017;17(1):2.
- Oh-Oka H. Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. Urology. 2017;106:50–4.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.